Last reviewed · How we verify
Eye Drops, Lubricant
Lubricating eye drops provide moisture and form a protective film over the ocular surface to relieve dryness and irritation.
Lubricating eye drops provide moisture and form a protective film over the ocular surface to relieve dryness and irritation. Used for Dry eye syndrome / Keratoconjunctivitis sicca, Ocular irritation and discomfort.
At a glance
| Generic name | Eye Drops, Lubricant |
|---|---|
| Sponsor | Eximore Ltd. |
| Drug class | Lubricating agent / Artificial tears |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Lubricant eye drops contain viscous agents (such as carboxymethylcellulose, hyaluronic acid, or mineral oil) that mimic natural tears and coat the cornea and conjunctiva. They reduce friction between the eyelid and eye surface, decrease evaporation of tear film, and provide symptomatic relief of dry eye symptoms. These drops do not address underlying tear production deficiency but provide temporary comfort and protection.
Approved indications
- Dry eye syndrome / Keratoconjunctivitis sicca
- Ocular irritation and discomfort
Common side effects
- Transient blurred vision
- Eye irritation or stinging
- Allergic reaction (rare)
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eye Drops, Lubricant CI brief — competitive landscape report
- Eye Drops, Lubricant updates RSS · CI watch RSS
- Eximore Ltd. portfolio CI